Groepsleider: Prof.dr. Leontien Kremer, pediatrician
Survivorship onderzoek
Nog vele jaren na behandeling hebben mensen die als kind kanker hebben gehad (survivors van kinderkanker) een aanzienlijk risico op het ontwikkelen van lange termijn effecten ten gevolge van hun eerdere behandeling van kanker. Onze groep focust op het kwantificeren van de rol van de behandeling van kinderkanker en andere belangrijke risicofactoren die impact hebben op de gezondheid en kwaliteit van leven, en op het ontwikkelen, valideren en implementeren van predictiemodellen en mogelijke (eHealth) interventies.
Onze groep werkt samen met de LATER-polikliniek, TDC-LATER en survivors. In Nederland hebben we meer dan 12,000 5-jaar survivors geïdentificeerd die tussen 1963 en 2014 behandeld zijn voor kinderkanker. Hiervan hebben meer dan 6,000 survivors deelgenomen aan een multidisciplinaire nationale studie genaamd de Dutch Childhood Cancer Survivor Study 1 (DCCSS-LATER 1). Hierbij zijn gegevens verzameld over de diagnose en behandeling, gezondheid, leefstijl en het psychosociaal functioneren middels vragenlijsten, en gezondheidsuitkomsten via koppelingen met gezondheidsregisters. In de vervolgstudie, de DCCSS-LATER 2, bezochten ongeveer 2400 survivors de LATER-poli waarbij medische gegevens en bloedmonsters verzameld zijn voor verder onderzoek. Het nationale LATER onderzoek is uniek in de wereld. Lopende onderzoeksonderwerpen waar we ons mee bezig houden zijn ziektelast, tweede tumoren, cardiovasculaire toxiciteit, vruchtbaarheid, leefstijl, veroudering, sterfte, broosheid/kwetsbaarheid, vermoeidheid, psychosociale gezondheid, bestralingsepidemiologie, lasten voor de gezondheidszorg en evaluatie van zorg.
Internationaal zijn we partner in het Europese PanCareSurFup project en ligt onze focus op hartziekten na behandeling voor kinderkanker en het ontwikkelen van richtlijnen, waaronder zorgmodellen en transitie van zorg. In het Europese PanCareLIFE project focussen we op de ontwikkeling van richtlijnen voor vruchtbaarheid en het behoud daarvan. Hiernaast geeft Leontien Kremer leiding aan de Europese PanCareFollowUp studie over de implementatie van survivorship zorg in vier landen en de ontwikkeling van een eHealth leefstijl interventie. Daarnaast voeren we studies uit in samenwerking met de Childhood Cancer Survivor Study, Verenigde Staten.
Systematische reviews, richtlijnen en uitkomstindicatoren voor zorg
Systematische reviews worden in de huidige tijd van evidence-based geneeskunde steeds waardvoller. Zij geven een helder inzicht in de meest recente wetenschappelijke kennis en liggen ten grondslag aan specifieke onderzoeksvragen of maken het gebrek daaraan duidelijk. Ze zijn het startpunt voor nieuwe klinische onderzoeken in kinderoncologie. Tevens vormen ze de basis voor richtlijnen. Richtlijnen zijn essentieel om de onderzoeksresultaten te vertalen naar de dagelijkse klinische praktijk.
Binnen het Prinses Máxima Centrum voor kinderoncologie ondersteunt de Systematische Review & Richtlijn Unit zowel Cochrane systematische reviews als andere soorten systematische reviews over kinderkanker.
Verder voorziet onze groep in evidence-based methodologie voor het ontwikkelen van richtlijnen binnen kinderoncologie. We ontwikkelen internationaal geharmoniseerde richtlijnen voor de lange termijn follow-up zorg voor survivors en voor het behoud van vruchtbaarheid voor kinderen met kanker, en ontwikkelen nationale en internationale supportive care richtlijnen. Hiernaast richten we ons de ontwikkeling van uitkomstindicatoren om de kwaliteit van zorg in kaart te brengen. Leontien Kremer is de oprichter en co-chair van de IGHG, samen met Melissa Hudson van het St. Jude Children’s Research Hospital, Memphis, Verenigde Staten.
Handboek systematische reviews PMC
Handboek richtlijnen IGHG
Meer informatie
Links
Geplande promoties:
- 27 november 2024 16.15 uur in Utrecht: Kim van Teunenbroek "Towards optimized paediatric palliative care: a Clinical Practice Guideline"
- 10 december 2024 14.15 uur in Utrecht: Aimée Westerveld "On the road to optimizing long-term survival. Subsequent neoplasms in childhood cancer survivors across five decades"
- 21 januari 2025 14.15 uur in Utrecht: Ismay de Beijer "Implementing optimal survivorship care"
- 4 juni 2024 14.15 uur in Utrecht: Rebecca van Kalsbeek "Improving quality of survival after childhood cancer by developing, implementing and evaluating care"
- 14 september 2023 10.15 uur in Utrecht: Yuehan Wang "Subsequent breast cancer risk in childhood cancer survivors and survivorship care"
- 19 september 2023 16.00 uur in de Agnietenkapel, Amsterdam: Juliette Stolze "Oral health in cancer survivors. Especially in those treated during childhood"
- 10 oktober 2023 16.00 uur in de Agnietenkapel, Amsterdam: Jan Leerink "Blood biomarkers and cardiac surveillance in childhood cancer survivors"
- 12 oktober 2023 14.15 uur in Utrecht: Esmée de Baat "Cardiotoxicity in childhood cancer survivors: risk of low dose cancer treatment, added value of ECG in surveillance and prevention by dexrazoxane"
Een pdf van het proefschrift is ook op te vragen bij: admingroepkremer@prinsesmaximacentrum.nl
Media and news
- Verbeteringen in LATER-kennis hebben meteen effect op de zorg
- 15-17 juni International Symposium on Late Complications after Childhood Cancer (ISLCCC) 2023
- Risico voor tweede tumoren na kinderkanker: Internationale studie met individuele patiënten gegevens- Kika subsidie 525 (2025-2029)
- Epidemiologie en Kwaliteit van zorg en Organisatie in de kinderpalliatieve zorg (EKO) (with UMCGroningen) – ZonMW grant (2025-2028)
- Metabool syndroom en vasculaire schade in relatie tot versnelde veroudering bij overlevenden van hematopoëtische stamceltransplantatie voor hematologische maligniteit (MetVasA) - Kika subsidie 433 (2023-2027)
- Vroege identificatie van overlevenden van kinderkanker met een hoog risico op late ontsteking van cardiomyopathie: Een kunstmatige intelligentie benadering met behulp van elektrocardiografie - NIH subsidie (2022-2026)
- Revisie richtlijn "Palliatieve zorg voor kinderen" (met UMCG)- IKNL subsidie (2020 -2025)
- Individueel zorgplan op basis van de richtlijn voor kinderpalliatieve zorg (with UMCGroningen– ZonMW grant (2020-2023)
- EU H2020 - PanCareSurPass: Opschaling en implementatie van het digitale Overlevingspaspoort om persoonsgerichte zorg voor overlevenden van kinderkanker te verbeteren (2021-2025)
- International Study of Subsequent Colorectal Cancer Among Survivors of Childhood, Adolescent, and Young Adult Cancers- NIH grant (2022-2025): Jop Teepen & Leontien Kremer projectleiders
- EU4HEALTH SmartCARE - smartcard-applicatie ter verbetering van de levenskwaliteit van overlevenden van kanker (2023-2024): Leontien Kremer, Heleen van der Pal, Renée Mulder projectleiders, Selina van den Oever PhD-student
- Innovaties voor de LATER richtlijn follow-up kinderkanker: ontwikkeling en implementatie – ZonMW grant (2021-2025)
- EU4HEALTH - EU network of Youth Cancer Survivors (2022-2024)
- EU H2020 - PanCare Follow Up: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers (2019-2023)
- Vroege detectie van cARdiovascuLar toxicitY bij kinderen met kanker - Kika grant 365 (PI Kremer/Mavinkurve-Groothuis (2020-2023)
- Máxima subsidie: Risico en tijdstrends van latere tumoren na vijf decennia behandeling van kinderkanker (2020-2024)
Risicofactoren voor borstkanker bij vrouwen na behandeling voor kanker bij kinderen en adolescenten - Kika-beurs 325 (2018-2023) - Vroege detectie van hartdysfunctie bij overlevenden van kanker bij kinderen; een DCOG LATER studie - Hartstichting (2017-2022)
- Saskia Puijm: genomineerd voor ‘supervisor of the year 2022 award’ UU, PhD council of the Graduate School of Life Sciences.
- Lieke Feijen en Elvira van Dalen: prijs voor beste abstract en-poster bij de International pediatric cardio-oncology conference (Cincinnatti)
- Kim van Teunenbroek: genomineerd bij de Máxima Research Retreat voor haar werk voor de herziening van de richtlijn palliatieve zorg voor kinderen.
- Yuehan Wang: genomineerd voor de Tom Voûte award “Breast cancer risk after anthracyclines for childhood cancer: an international pooled analysis”. En ze won de prijs voor jonge onderzoekers van SIOP 2023. Deze prijzen zijn bedoeld om jonge onderzoekers, werkzaam op het gebied van kinderoncologie, de kans te geven hun originele onderzoek te presenteren op de jaarlijkse SIOP-bijeenkomst.
- Rebecca van Kalsbeek heeft de Tom Voûte award gewonnen voor haar presentatie "Measuring quality after survival after childhood cancer" .
Ainsbury EA, Dalke C, Hamada N, Benadjaoud MA, Chumak V, Ginjaume M, Kok JL, Mancuso M, Sabatier L, Struelens L, Thariat J, Jourdain JR. Radiation-induced lens opacities: Epidemiological, clinical and experimental evidence, methodological issues, research gaps and strategy. Environ Int. 2021 Jan;146:106213
Bardi E, Mulder RL, van Dalen EC, Bhatt NS, Ruble KA, Burgis J, et al. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. Cancer Treat Rev. 2021;100:102296
Bowers DC, Verbruggen LC, Kremer LCM, Hudson MM, Skinner R, Constine LS, et al. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(5):e196-e206
Byrne J, Schmidtmann I, Rashid H, Hagberg O, Bagnasco F, Bardi E, et al. Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer: the PanCareSurFup consortium. Int J Cancer. 2021.
Dekker BL, Muller Kobold AC, Brouwers AH, Williams GR, Nies M, Klein Hesselink MS, et al. Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: A Longitudinal Follow-Up Study. Thyroid. 2021.
Feijen EAM, van Dalen EC, van der Pal HJH, Reulen RC, Winter DL, Keuhni CE, et al. Increased risk of cardiac ischaemia in a pan-European cohort of 36 205 childhood cancer survivors: a PanCareSurFup study. Heart. 2021;107(1):33-40.
Goldkuhle M, Bender R, Akl EA, van Dalen EC, Nevitt S, Mustafa RA, Guyatt GH, Trivella M, Djulbegovic B, Schünemann H, Cinquini M, Kreuzberger N, Skoetz N; GRADE Working Group. GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes-Study limitations due to censoring of participants with missing data in intervention studies. J Clin Epidemiol. 2021 Jan;129:126-137.
Haveman LM, van Ewijk R, van Dalen EC, Breunis WB, Kremer LC, van den Berg H, Dirksen U, Merks JH. High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD011405
Leerink JM, van de Ruit M, Feijen EAM, Kremer LCM, Mavinkurve-Groothuis AMC, Pinto YM, et al. Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis. J Mol Med (Berl). 2021;99(9):1195-207.
Leerink JM, van der Pal HJH, Kremer LCM, Feijen EAM, Meregalli PG, Pourier MS, et al. Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer. JACC CardioOncol. 2021;3(1):62-72.
Kieran MW, Caron H, Winther JF, Henderson TO, Haupt R, Hjorth L, et al. A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence. Pediatr Blood Cancer. 2021;68(7):e29047.Lebbink CA, Ringers TP, Schouten-van Meeteren AYN, van Iersel L, Clement SC, Boot AM, et al. Prevalence and risk factors of hypothalamic-pituitary dysfunction in infant and toddler childhood brain tumor survivors. Eur J Endocrinol. 2021;185(4):597-606.
Lo AC, Ronckers C, Aznar MC, Avanzo M, van Dijk I, Kremer LCM, et al. Breast Hypoplasia and Decreased Lactation From Radiation Therapy in Survivors of Pediatric Malignancy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2021.
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64.
Merkx R, Leerink JM, de Baat EC, Feijen EAM, Kok WEM, Mavinkurve-Groothuis AMC, et al. Asymptomatic systolic dysfunction on contemporary echocardiography in anthracycline-treated long-term childhood cancer survivors: a systematic review. J Cancer Surviv. 2021.
Merkx R, Leerink JM, Feijen E, Kremer LCM, de Baat EC, Bellersen L, et al. Echocardiography protocol for early detection of cardiac dysfunction in childhood cancer survivors in the multicenter DCCSS LATER 2 CARD study: Design, feasibility, and reproducibility. Echocardiography. 2021;38(6):951-63.
Moskowitz CS, Ronckers CM, Chou JF, Smith SA, Friedman DN, Barnea D, et al. Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. J Clin Oncol. 2021;39(27):3012-21.
Mulder RL, Font-Gonzalez A, Green DM, Loeffen EAH, Hudson MM, Loonen J, et al. Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e57-e67.
Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, Loeffen EAH, Burns KC, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e45-e56.
Mulder RL, Font-Gonzalez A, van Dulmen-den Broeder E, Quinn GP, Ginsberg JP, Loeffen EAH, et al. Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e68-e80.
Palmer JD, Tsang DS, Tinkle CL, Olch AJ, Kremer LCM, Ronckers CM, et al. Late effects of radiation therapy in pediatric patients and survivorship. Pediatr Blood Cancer. 2021;68 Suppl 2:e28349.
Penson A, van Deuren S, Bronkhorst E, Keizer E, Heskes T, Coenen MJH, et al. Methodology of the DCCSS later fatigue study: a model to investigate chronic fatigue in long-term survivors of childhood cancer. BMC Med Res Methodol. 2021;21(1):106.
Pluijm SMF. Accelerated Aging as a Paradigm to Understand the Late Effects of Cancer Therapies. Front Horm Res. 2021;54:1-9.
Pluimakers V, Fiocco M, van Atteveld J, Hobbelink M, Bresters D, Van Dulmen-den Broeder E, et al. Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS). JMIR Res Protoc. 2021;10(1):e21256.
Roshandel R, van Dijk M, Overbeek A, Kaspers G, Lambalk C, Beerendonk C, et al. Female reproductive function after treatment of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(4):e28894.
Schulpen M, Visser O, Reedijk AMJ, Kremer LCM, Zwaan CM, Eggermont AMM, et al. Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s. Eur J Cancer. 2021;157:81-93.
Vaarwerk B, Breunis WB, Haveman LM, de Keizer B, Jehanno N, Borgwardt L, van Rijn RR, van den Berg H, Cohen JF, van Dalen EC, Merks JHM. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung and lymph node metastases in rhabdomyosarcoma. Cochrane Database of Systematic Reviews (accepted for publication).
Vallianatos S, Huizinga CSM, Schuiling-Otten MA, Schouten-van Meeteren AYN, Kremer LCM, Verhagen AAE. Development of the Dutch Structure for Integrated Children's Palliative Care. Children (Basel). 2021;8(9).
van Atteveld JE, de Groot-Kruseman HA, Fiocco M, Lequin MH, Neggers S, Pluijm SMF, et al. Effect of post-consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols. Haematologica. 2021;106(4):1198-201.
van Atteveld JE, Mulder RL, van den Heuvel-Eibrink MM, Hudson MM, Kremer LCM, Skinner R, et al. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes Endocrinol. 2021;9(9):622-37.
van Dalen EC, Mulder RL, Suh E, Ehrhardt MJ, Aune GJ, Bardi E, et al. Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Eur J Cancer. 2021;156:127-37.
van den Oever, SR, Pluijm SMF, Skinner R, Glaser A, Mulder RL, Armenian S, et al. Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns. J Cancer Surviv (accepted for publication).
van der Kooi ALF, Mulder RL, Hudson MM, Kremer LCM, Skinner R, Constine LS, et al. Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Am J Obstet Gynecol. 2021;224(1):3-15.
van der Kooi ALF, van Dijk M, Broer L, van den Berg MH, Laven JSE, van Leeuwen FE, Lambalk CB, Overbeek A, Loonen JJ, van der Pal HJ, Tissing WJ, Versluys B, Bresters D, Beerendonk CCM, Ronckers CR, van der Heiden-van der Loo M, Kaspers GL, de Vries ACH., . . . Pluijm SMF, Spix C, Zolk O, Kaatsch P, Krijthe JH, Kremer LC, Yasui Y, Brooke RJ, Uitterlinden AG, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. Hum Reprod. 2021 Mar 18;36(4):1120-1133.
van der Perk MEM, Broer L, Yasui Y, Robison LL, Hudson MM, Laven JSE, et al. Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers (Basel). 2021;13(18).
van Erp LME, Maurice-Stam H, Kremer LCM, Tissing WJE, van der Pal HJH, de Vries ACH, et al. Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study. Eur J Cancer. 2021;152:204-14.
van Erp LME, Maurice-Stam H, Kremer LCM, Tissing WJE, van der Pal HJH, de Vries ACH, et al. A vulnerable age group: the impact of cancer on the psychosocial well-being of young adult childhood cancer survivors. Support Care Cancer. 2021;29(8):4751-61.
van Hulst AM, Verwaaijen EJ, Fiocco MF, Pluijm SMF, Grootenhuis MA, Pieters R, et al. Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design. BMC Pediatr. 2021;21(1):427.
van Kalsbeek RJ, Mulder RL, Skinner R, Kremer LCM. The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Front Horm Res. 2021;54:1-15.
van Kalsbeek RJ, van der Pal HJH, Hjorth L, Winther JF, Michel G, Haupt R, et al. The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers. Eur J Cancer. 2021;153:74-85.
van Kalsbeek RJ, van der Pal HJH, Kremer LCM, Bardi E, Brown MC, Effeney R, et al. European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. Eur J Cancer. 2021;154:316-28.
van Schaik J, van Roessel I, Schouten-van Meeteren N, van Iersel L, Clement SC, Boot AM, et al. High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. J Clin Oncol. 2021;39(11):1264-73.
Verbruggen LC, Kok JL, Teepen JC, Janssens GO, de Boer CM, Stalpers LJA, et al. Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study. Eur J Cancer. 2021;150:240-9.
Verwaaijen EJ, Ma J, de Groot-Kruseman HA, Pieters R, van der Sluis IM, van Atteveld JE, et al. A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. J Bone Miner Res. 2021.
2020
Christen S, Roser K, Mulder RL, Ilic A, Lie HC, Loonen JJ, et al. Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. J Cancer Surviv. 2020;14(6):923-38.
Clement SC, Lebbink CA, Klein Hesselink MS, Teepen JC, Links TP, Ronckers CM, van Santen HM. Presentation and outcome of subsequent thyroid cancer among childhood cancer survivors compared to sporadic thyroid cancer: a matched national study. Eur J Endocrinol. 2020 Aug;183(2):169-180
Coppes MJ, Kremer LCM. Surviving Survival-Challenge Accepted: Perspectives on Survivorship in Pediatric Oncology. Pediatr Clin North Am. 2020;67(6):xix-xxi.
Dixon SB, Chow EJ, Hjorth L, Hudson MM, Kremer LCM, Morton LM, et al. The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress. Pediatr Clin North Am. 2020;67(6):1237-51.,
Feijen EAM, van Dalen EC, van der Pal HJH, Reulen RC, Winter DL, Keuhni CE, Morsellino V, Alessi D, Allodji RS, Byrne J, Bardi E, Jakab Z, Grabow D, Garwicz S, Haddy N, Jankovic M, Kaatsch P, Levitt GA, Ronckers CM, Schindera C, Skinner R, Zalatel L, Hjorth L, Tissing WJE, De Vathaire F, Hawkins MM, Kremer LCM; PanCareSurFup consortium. (2020) Increased risk of cardiac ischaemia in a pan-European cohort of 36 205 childhood cancer survivors: a PanCareSurFup study. Heart. PMID: 32826285.
Gosselt HR, Verhoeven MMA, de Rotte MCFJ, Pluijm SMF, Muller IB, Jansen G, Tekstra J, Bulatović-Ćalasan M, Heil SG, Lafeber FPJG, Hazes JMW, de Jonge R. Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio. Rheumatol Ther. 2020 Dec;7(4):837-850.
Hawkins M, Bhatia S, Henderson TO, Nathan PC, Yan A, Teepen JC, Morton LM. Subsequent Primary Neoplasms: Risks, Risk Factors, Surveillance, and Future Research. Pediatr Clin North Am. 2020 Dec;67(6):1135-1154.
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, . . . ., Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O; PanCareLIFE consortium. Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data Brief. 2020 Aug 24;32:106227.
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, , . . . Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O; PanCareLIFE consortium. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. Eur J Cancer. 2020 Oct;138:212-224.
Lebbink CA, Lentjes EGWM, Tissing WJE, van den Heuvel-Eibrink MM, van Santen HM, van Dalen EC. Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer. Cochrane Database of Systematic Reviews 2020, Issue 12. Art. No.: CD013805.
Leerink JM, Feijen ELAM, van der Pal HJH, Kok WEM, Mavinkurve-Groothuis AMC, Kapusta L, Pinto YM, Maas AHEM, Bellersen L, Teske AJ, Ronckers CM, Louwerens M, van Dalen EC, van Dulmen-den Broeder E, Batenburg L, van der Heiden-van der Loo M, van den Heuvel-Eibrink MM, van Leeuwen FE, de Vries ACH, Weijers G, de Korte CL, Loonen JJ, Neggers SJCMM, Versluys ABB, Tissing WJE, Kremer LCM; LATER Study Group. Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study. Am Heart J. 2020 Jan;219:89-98.
Leerink JM, de Baat EC, Feijen EAM, Bellersen L, van Dalen EC, Grotenhuis HB, Kapusta L, Kok WEM, Loonen J, van der Pal HJH, Pluijm SMF, Teske AJ, Mavinkurve-Groothuis AMC, Merkx R and Kremer LCM. (2020) Cardiac Disease in Childhood Cancer Survivors. JACC: CardioOncology. 2020;2:363-378. PMID
Loeffen EAH, Mulder RL, Font-Gonzalez A, Leroy P, Dick BD, Taddio A, et al. Reducing pain and distress related to needle procedures in children with cancer: A clinical practice guideline. Eur J Cancer. 2020;131:53-67.
Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neurooncol Adv. 2020;2(1):vdaa122.
Mulder RL, van Kalsbeek RJ, Hudson MM, Skinner R, Kremer LCM. The Critical Role of Clinical Practice Guidelines and Indicators in High-Quality Survivorship After Childhood Cancer. Pediatr Clin North Am. PMID: 33131535.
Mulder RL, Hudson MM, Bhatia S, Landier W, Levitt G, Constine LS, Wallace WH,van Leeuwen FE, Ronckers CM, Henderson TO, Moskowitz CS, Friedman DN, Ng AK, Jenkinson HC, Demoor-Goldschmidt C, Skinner R, Kremer LCM, Oeffinger KC. (2020) Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. J Clin Oncol. PMID: 33078972
Nies M, Cantineau AEP, Arts E, van den Berg MH, van Leeuwen FE, Muller Kobold AC, et al. Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma. Thyroid. 2020;30(8):1169-76.
Reedijk AMJ, Zijtregtop EAM, Coebergh JWW, Meyer-Wentrup FAG, Hebeda KM, Zwaan CM, Janssens GOR, Pieters R, Plattel WJ, Dinmohamed AG, Zijlstra JM, Kremer LCM, Lugtenburg PJ, Beishuizen A, Karim-Kos HE. (2020) Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015. Br J Haematol. PMID: 32030738.
Reulen RC, Wong KF, Bright CJ, Winter DL, Alessi D, Allodji RM, Bagnasco F, Bárdi E, Bautz A, Byrne J, Feijen EA….. Teepen JC, Veres C, Zrafi W, Debiche G, Llanas D, Terenziani M, Vu-Bezin G, Wesenberg F, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki PM, Zadravec Zaletel L, Kuehni CE, Winther JF, de Vathaire F, Kremer LC, Hjorth L, Hawkins MM. Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study. Gut. 2020 Nov 2:gutjnl-2020-322237
Schulte F, Forbes C, Wurz A, Patton M, Russell KB, Pluijm S, Krull KR. Childhood Cancer Survivorship: Daily Challenges. Pediatr Clin North Am. 2020 Dec;67(6):1083-1101.
Skoetz N, Goldkuhle M, van Dalen EC, Akl EA, Trivella M, Mustafa RA, Nowak A, Dahm P, Schünemann H, Bender R; GRADE Working Group (2020). GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. J Clin Epidemiol. PMID: 31711910.
Streefkerk N, Fioole LCE, Beijer JGM, Feijen ELAM, Teepen JC, Winther JF, Ronckers CM, Loonen JJ, van Dulmen-den Broeder E, Skinner R, Hudson MM, Tissing WJE, Korevaar JC, Mulder RL, Kremer LCM. Large variation in assessment and outcome definitions to describe the burden of long-term morbidity in childhood cancer survivors: A systematic review. Pediatr Blood Cancer. PMID: 32881287.
Streefkerk N, Tissing WJE, Korevaar JC, van Dulmen-den Broeder E, Bresters D, van der Heiden-van der Loo M, van de Heuvel-Eibrink MM, Van Leeuwen FE, Loonen J, van der Pal HHJ, Ronckers CM, Versluys AB, de Vries ACH, Feijen EAM, Kremer LCM; Dutch LATER Study Group. (2020) A detailed insight in the high risks of hospitalizations in long-term childhood cancer survivors-A Dutch LATER linkage study. PLoS One. PMID: 32427994
Streefkerk N, Tissing WJE, van der Heiden-van der Loo M, Lieke Feijen EAM, van Dulmen-den Broeder E, Loonen JJ, et al. The Dutch LATER physical outcomes set for self-reported data in survivors of childhood cancer. J Cancer Surviv. 2020;14(5):666-76.
Tas, M. L., Reedijk, A. M. J., Karim-Kos, H. E., Kremer, L. C. M., van de Ven, C. P., Dierselhuis, M. P., . . . van Noesel, M. M. (2020). Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. European journal of cancer (Oxford, England : 1990). PMID: 31726247
Van As JW, van den Berg H, van Dalen EC. (2020) Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev. 2020 Jan 21;1(1):CD010885.
Van Dalen EC. Cochrane Childhood Cancer and COVID-19: developing recommendations for childhood, adolescent and young adult cancer survivors. In: Collaborating in response to COVID-19: editorial and methods initiatives across Cochrane. Cochrane Database of Systematic Reviews 2020;(12 Suppl 1):63-64.
Verbruggen LC, Wang Y, Armenian SH, Ehrhardt MJ, van der Pal HJH, van Dalen EC, van As JW, ., . . . van den Oever SR, Pavasovic V, Sato S, Schulte F, Sung L, Tissing W, Uyttebroeck A, Mulder RL, Kuehni C, Skinner R, Hudson MM, Kremer LCM. Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2020 Dec;67(12):e28702. PMID: 32969160
Verbruggen LC, Hudson MM, Bowers DC, Ronckers CM, Armstrong GT, Skinner R, Hoving EW, Janssens GO, van der Pal HJH, Kremer LCM, Mulder RL. (2020) Variations in screening and management practices for subsequent asymptomatic meningiomas in childhood, adolescent and young adult cancer survivors. J Neurooncol. PMID: 32088813.
2019
Allodji, R. S., Hawkins, M. M., Bright, C. J., Fidler-Benaoudia, M. M., Winter, D. L., Alessi, D., . . . Reulen, R. C. (2019). Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. European journal of cancer (Oxford, England : 1990). PMID: 31260818
Brennan-Jones CG, McMahen C, Van Dalen EC (2019). Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer. Int J Audiol. PMID: 30545270
Clemens, E., Broer, L., Langer, T., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., . . . PanCare, L. c. (2019). Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. The pharmacogenomics journal. PMID: 31666714
Clemens, E., Meijer, A. J., Broer, L., Langer, T., van der Kooi, A.-L. L., Uitterlinden, A. G., . . . van den Heuvel-Eibrink, M. M. (2019). Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR research protocols. PMID: 30888333
Clemens, E., van den Heuvel-Eibrink, M. M., Mulder, R. L., Kremer, L. C. M., Hudson, M. M., Skinner, R., . . . International Guideline Harmonization Group ototoxicity, g. (2019). Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. The Lancet. Oncology. PMID: 30614474
Clemens E, Broer L, Langer T, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, …. Kremer LC, Kruseova J, Kuehni CE, van der Pal H, Parfitt R, Deuster D, Matulat P, Spix C, Tillmanns A, Tissing WJE, Maier L, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM; PanCareLIFE consortium. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics J. 2020 Apr;20(2):294-305.
Constine, L. S., Ronckers, C. M., Hua, C. H., Olch, A., Kremer, L. C. M., Jackson, A., & Bentzen, S. M. (2019). Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Analyse Normal Tissue Radiation Dose-Volume Response Relationships for Paediatric Cancer Patients. Clinical oncology (Royal College of Radiologists (Great Britain)). PMID: 30670336
Dreesens, D., Kremer, L., & van der Weijden, T. (2019). The Dutch chaos case: A scoping review of knowledge and decision support tools available to clinicians in the Netherlands. Health policy (Amsterdam, Netherlands). PMID: 31722782
Dreesens, D., Stiggelbout, A., Agoritsas, T., Elwyn, G., Flottorp, S., Grimshaw, J., . . . van der Weijden, T. (2019). A conceptual framework for patient-directed knowledge tools to support patient-centred care: Results from an evidence-informed consensus meeting. Patient education and counseling. PMID: 31118137
Dreesens, D., Veul, L., Westermann, J., Wijnands, N., Kremer, L., van der Weijden, T., & Verhagen, E. (2019). The clinical practice guideline palliative care for children and other strategies to enhance shared decision-making in pediatric palliative care; pediatricians' critical reflections. BMC pediatrics. PMID: 31783822
Feijen, E. A. M., Leisenring, W. M., Stratton, K. L., Ness, K. K., van der Pal, H. J. H., van Dalen, E. C., . . . Chow, E. J. (2019). Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA oncology. PMID: 30703192
Feijen, E. A. M. L., Font-Gonzalez, A., Van der Pal, H. J. H., Kok, W. E. M., Geskus, R. B., Ronckers, C. M., . . . Group, D. L. S. (2019). Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study. Journal of the American Heart Association. PMID: 30595059
Kok, J. L., Teepen, J. C., van der Pal, H. J., van Leeuwen, F. E., Tissing, W. J. E., Neggers, S. J. C. M. M., . . . Group, D.-L. S. (2019). Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer. JAMA oncology. PMID: 30920605
Kok, J. L., Teepen, J. C., van Leeuwen, F. E., Tissing, W. J. E., Neggers, S. J. C. M. M., van der Pal, H. J., . . . Ronckers, C. M. (2019). Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro-oncology. PMID: 30099534
Kooijmans EC, Bökenkamp A, Tjahjadi NS, Tettero JM, van Dulmen-den Broeder E, van der Pal HJ, Veening MA (2019). Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. PMID: 30855726
Leerink, J. M., Verkleij, S. J., Feijen, E. A. M., Mavinkurve-Groothuis, A. M. C., Pourier, M. S., Ylänen, K., . . . Kok, W. E. M. (2019). Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review. Heart (British Cardiac Society). PMID: 30158136
Loeffen, E. A. H., Knops, R. R. G., Boerhof, J., Feijen, E. A. M. L., Merks, J. H. M., Reedijk, A. M. J., . . . Tissing, W. J. E. (2019). Treatment-related mortality in children with cancer: Prevalence and risk factors. European journal of cancer (Oxford, England : 1990). PMID: 31569066
Loeffen, E. A. H., Kremer, L. C. M., van de Wetering, M. D., Mulder, R. L., Font-Gonzalez, A., Dupuis, L. L., . . . Pain in Children with Cancer Guideline Development, P. (2019). Reducing pain in children with cancer: Methodology for the development of a clinical practice guideline. Pediatric blood & cancer. PMID: 30848078
Michel, G., Mulder, R. L., van der Pal, H. J. H., Skinner, R., Bárdi, E., Brown, M. C., . . . Levitt, G. (2019). Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. Journal of cancer survivorship : research and practice. PMID: 31396878
Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YKK, Post PN, Postma A, Szőnyi LP, Levitt GA, Bardi E, Skinner R, van Dalen EC (2019). Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database Syst Rev. PMID: 30985922
Peinemann F, van Dalen EC, Enk H, Tytgat GA (2019). Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. PMID: 31016728
Reedijk, A. M. J., Klein, K., Coebergh, J. W. W., Kremer, L. C., Dinmohamed, A. G., de Haas, V., . . . Karim-Kos, H. E. (2019). Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia. PMID: 30568171
Skoetz N, Goldkuhle M, Weigl A, Dwan K, Labonté V, Dahm P, Meerpohl JJ, Djulbegovic B, van Dalen EC. Methodological review showed correct absolute effect size estimates for
time-to-event outcomes in less than one-third of cancer-related systematic reviews. J Clin Epidemiol. 2019 Apr;108:1-9.
Streefkerk, N., Heins, M. J., Teepen, J. C., Feijen, E. A. M., Bresters, D., van Dulmen-den Broeder, E., . . . Group, D.-L. S. (2019). The involvement of primary care physicians in care for childhood cancer survivors. Pediatric blood & cancer. PMID: 31033160
Teepen, J. C., Kok, J. L., Kremer, L. C., Tissing, W. J. E., van den Heuvel-Eibrink, M. M., Loonen, J. J., . . . Group, D.-L. S. (2019). Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study. Journal of the National Cancer Institute. PMID: 30802904
Teepen, J. C., Kremer, L. C., van der Heiden-van der Loo, M., Tissing, W. J., van der Pal, H. J., van den Heuvel-Eibrink, M. M., . . . Group, D.-L. S. (2019). Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort. Cancer causes & control : CCC. PMID: 31300947
Teepen, J. C., Ronckers, C. M., & Kremer, L. C. M. (2019). Colorectal Cancer Screening in Childhood Cancer Survivors. Journal of the National Cancer Institute. PMID: 30980664
Ten Berg, S., Loeffen, E. A. H., van de Wetering, M. D., Martens, D. H. J., van Ede, C. M., Kremer, L. C. M., & Tissing, W. J. E. (2019). Development of pediatric oncology supportive care indicators: Evaluation of febrile neutropenia care in the north of the Netherlands. Pediatric blood & cancer. PMID: 30318786
Vaarwerk, B., Schoot, R. A., Maurice-Stam, H., Slater, O., Hartley, B., Saeed, P., . . . Merks, J. H. M. (2019). Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma. Pediatric blood & cancer. PMID: 30318743
Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children withcancer.CochraneDatabase Syst Rev. PMID: 31063591
Van de Loo, L. E. X. M., van den Berg, M. H., Overbeek, A., van Dijk, M., Damen, L., Lambalk, C. B., . . . Group, D. L.-V. S. (2019). Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors. Fertility and sterility. PMID: 30691634